Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Relative Burden of Cancer-Related Death Exceeds Non-Cancer Deaths in Older Adults Selected for Surgery

August 16, 2021
By Ariana Pelosci
Article

At a population level, those who were selected for surgery had a greater risk of dying from cancer related causes than dying from non-cancer causes.

The relative burden of cancer-related mortality at the population level exceeded non-cancer related deaths in older adults selected for surgery, according to a study published in JAMA Surgery.

At a median follow-up of 46 months, among adults who underwent surgery, 49.6% of deaths (n = 16,900/34,044) were cancer related. Moreover, when reporting the cumulative estimated 5-year incidence of cancer death, investigators noted that the incidence of cancer-related death (20.7%; 95% CI, 16.2%-16.8%) was greater compared with noncancer mortality (16.5%; 95% CI, 16.2%-16.8%). At 1-year the estimated cumulative incidence of cancer death following surgery was 8.2% (95% CI, 8.4%-8.6%), at 3 years it was 16.4% (95% CI, 16.2%-16.7%), and at 5 years it was 20.7% (95% CI, 20.4%-21.0%).

“This is the first study, to our knowledge, to describe the population-level overall prognosis of older adults after cancer surgery including an analysis of cancer and noncancer deaths,” the investigators wrote. “The relative burden of cancer compared with noncancer deaths varied by cancer type, age group, and preoperative frailty status. Noncancer deaths became greater than cancer deaths only in patients who underwent a surgical procedure for breast cancer or melanoma, who were 85 years and older, and with preoperative frailty.”

The study identified 82,037 older adults who were going to undergo surgical resection for cancer. The most common types of cancer were breast cancer (27.8%; n = 22,811) and gastrointestinal cancer (39.1%; n = 32,036). Patients with postoperative mortality within 90 days of surgery were responsible for 11.2% (n = 3831) of deaths.

Additional findings from the study indicated that the estimated cumulative incidence of non-cancer death after surgery at 1-year was 5.3% (95% CI, 5.1%-5.5%), at 3-years it was 11.9% (95% CI, 11.6%-12.2%), and at 5-years it was 18.1% (95% CI, 17.8%-18.5%).

For all cancer types, the cumulative incidence of all cause death varied at 5-years from 22.0% (95% CI, 21.4%-22.6%) to 50.8% (95% CI, 47.2%-54.4%). The lowest 5-year cumulative incidence of death occurred in patients with breast cancer at 9.1% (95 % CI, 8.6%-9.5%) and the highest was oropharyngeal cancer at 29.1% (95% CI, 25.9%-32.3%).

Across most cancer types, the incidence of death was higher in cancer-related causes vs non-cancer death. However, the 2 exceptions were breast cancer and melanoma, which over the 5-year noncancer deaths were higher than cancer deaths. Although the cumulative incidence of non-cancer death was similar across gastrointestinal cancers, cancer-related death was varied, with the highest cumulative incidence being noted in hepato-pancreatico-biliary cancer and esophageal cancer. Those with bladder cancer had the greatest incidence of cancer death among all genitourinary malignancies.

Patients with advancing age were found to have a higher all-cause death at 5 years that ranged from 26.4% (95% CI, 25.8%-26.9%) to 57.0% (95% CI, 56.0%-58.1%). Investigators theorize that the increase in non-cancer death can be attributed to patients growing older. Patients who were 85 years or older had a greater incidence of death from cancer than from non-cancer deaths 5 years post-surgery surgery.

Investigators also identified an association between preoperative frailty and an increased risk of death and identified patterns in cause of death. For patients without frailty, the all-cause death at 5-years was 34.9% (95% CI, 34.9%-35.3%) vs 56.6% (95% CI, 55.2%-58.0%) in patients who were considered frail prior to surgery. Those with frailty pre-surgery had a greater incidence in death from non-cancer causes starting 3-years post-surgery.

Advancing age was associated with cumulative incidence of cancer death among patients aged 75 to 79 years (sub-distribution HR, 1.33; 95% CI, 1.28-1.38) to 85 years or older (sub-distribution HR, 2.06; 95% CI, 1.96-2.16) compared with those aged 70 to 74 years.

Patients with preoperative frailty were associated with increased cumulative incidence in death for both cancer and non-cancer death alike. The significance of the association between frailty and non-cancer death increased with age (P<.001), and no interaction was found for frailty/age and cancer deaths (P = .09).

All cancer types were strongly associated with an increased cumulative incidence of cancer, aside from breast cancer. The sub-distribution HR ranged from 2.34 (95% CI, 2.14-2.57) for melanoma to 4.69 (95% CI, 4.40-5.01) for bronchopulmonary cancer. This was not consistently observed for non-cancer deaths.

Investigators concluded that the data can be used to counsel patients and help assess patterns of over or under treatments, as well as refining selection criteria to treat older adults with cancer.

“Our study addresses these gaps in the literature by reporting on long-term survival outcomes for older adults undergoing cancer surgery stratified by cancer type, age, and preoperative frailty status and accounting for competing risks to avoid overestimation of the risk of cancer death in older adults. Previously, overall prognostic estimates for patients, clinicians, and health care systems planning were only available by applying data from younger patients,” they concluded.

Reference

Chesney TR, Coburn N, Mahar AL, et al. All-Cause and cancer-specific death of older adults following surgery for cancer. JAMA Surg. 2021;156(7):e211425. doi:10.1001/jamasurg.2021.1425

Recent Videos
Ronald Bleday, MD, stated that before standardizing a stepwise approach to treating surgical pain, providers might have overtreated patients with opioids.
Conducting trials safely within a community setting lies at the heart of a successful collaboration between Northwell Health and START.
The expertise of START's network may streamline the availability of clinical trial enrollment and novel treatment options among patients with cancer.
A new START center in New York may give patients with advanced malignancies an opportunity to access novel therapies in the community setting.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
Related Content
Advertisement

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 14th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Discussing Early ctDNA Detection Through MCED Blood Tests

Tim Cortese
July 31st 2025
Article

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Related Content
Advertisement

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.

New Unit Aims to Expand Trial and Therapy Options in The Community Setting

Russ Conroy
August 14th 2025
Article

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, shares how a new position presents a “good opportunity” to improve community-based clinical trial access.


Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.


Cellular therapies are a treatment modality that hold promise in various cancer types.

Cross-Collaboration is Key for Cellular Therapies Options Across Cancer Types

Tim Cortese
August 8th 2025
Article

The 2025 National ICE-T Symposium gave oncology experts an opportunity to share ideas regarding the administration of cellular therapies.


Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of pharmacology Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.


A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.

Discussing Early ctDNA Detection Through MCED Blood Tests

Tim Cortese
July 31st 2025
Article

A recently published study showed that a multicancer early detection blood test was able to identify cancer 3 or more years before a diagnosis.


The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Top Trials From the 2025 ASCO and EHA Meetings

Julie M. Vose, MD, MBA
July 25th 2025
Article

The 2025 ASCO Annual Meeting showcased groundbreaking oncology research and treatments, fostering collaboration among leading experts in the field.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.